The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2019 Feb 12

PMID 30740089

Citations 22

Authors

Xiaoshuang Liu

Chao Tang

Guodao Wen

Chunyu Zhong

Jin Yang

Junhao Zhu

Chiyuan Ma

Affiliations

Soon will be listed here.

Abstract

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms.

Citing Articles

MicroRNA networks in prolactinoma tumorigenesis: a scoping review.

Rad S, Nejadi Orang F, Shadbad M Cancer Cell Int. 2024; 24(1):418.

PMID: 39702128 PMC: 11660578. DOI: 10.1186/s12935-024-03529-5.

L-Dopa Might Be Insufficient to Suppress Development of Prolactinomas in Dihydropteridine Reductase-Deficiency Patients.

Diaz-Moreno U, Gan C, Pujari D, Gan H, Batzios S JCEM Case Rep. 2024; 2(10):luae172.

PMID: 39346013 PMC: 11427838. DOI: 10.1210/jcemcr/luae172.

Current and Perspective Approaches to the Treatment of Prolactinomas.

Tykhonova T, Barabash N, Kanishcheva O Acta Med Litu. 2024; 30(2):96-107.

PMID: 38516518 PMC: 10952428. DOI: 10.15388/Amed.2023.30.2.1.

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects.

Mastnak L, Herman R, Ferjan S, Janez A, Jensterle M Life (Basel). 2023; 13(11).

PMID: 38004264 PMC: 10672473. DOI: 10.3390/life13112124.

Targeting GDP-Dissociation Inhibitor Beta (GDI2) with a Benzo[]quinolizidine Library to Induce Paraptosis for Cancer Therapy.

Sun Y, Zheng H, Qian L, Liu Y, Zhu D, Xu Z JACS Au. 2023; 3(10):2749-2762.

PMID: 37885576 PMC: 10598831. DOI: 10.1021/jacsau.3c00228.

References

Melmed S . Pathogenesis of pituitary tumors. Endocrinol Metab Clin North Am. 1999; 28(1):1-12, v. DOI: 10.1016/s0889-8529(05)70055-4. View

Schnell S, You S, El Halawani M . D1 and D2 dopamine receptor messenger ribonucleic acid in brain and pituitary during the reproductive cycle of the turkey hen. Biol Reprod. 1999; 60(6):1378-83. DOI: 10.1095/biolreprod60.6.1378. View

Ying C . Potential involvement of tumor suppressor gene expression in the formation of estrogen-inducible pituitary tumors in rats. Endocr J. 2000; 47(1):1-5. DOI: 10.1507/endocrj.47.1. View

Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E . Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells. Biol Reprod. 2000; 62(6):1486-94. DOI: 10.1095/biolreprod62.6.1486. View

Yin , Tamaki , Kokunai , Yasuo , Yonezawa . Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression. J Clin Neurosci. 2000; 6(4):326-331. DOI: 10.1054/jocn.1998.0063. View

Usiello A, Baik J, Rouge-Pont F, Picetti R, Dierich A, Lemeur M . Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000; 408(6809):199-203. DOI: 10.1038/35041572. View

Sperandio S, de Belle I, Bredesen D . An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci U S A. 2000; 97(26):14376-81. PMC: 18926. DOI: 10.1073/pnas.97.26.14376. View

Colao A, Lombardi G, Annunziato L . Cabergoline. Expert Opin Pharmacother. 2001; 1(3):555-74. DOI: 10.1517/14656566.1.3.555. View

Ben-Jonathan N, Hnasko R . Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001; 22(6):724-63. DOI: 10.1210/edrv.22.6.0451. View

10.

Albert P, Robillard L . G protein specificity: traffic direction required. Cell Signal. 2002; 14(5):407-18. DOI: 10.1016/s0898-6568(01)00259-5. View

11.

Lincoln G, Clarke I . Noradrenaline and dopamine regulation of prolactin secretion in sheep: role in prolactin homeostasis but not photoperiodism. J Neuroendocrinol. 2002; 14(1):36-44. DOI: 10.1046/j.0007-1331.2001.00734.x. View

12.

Liu J, Baker R, Sun C, Sundmark V, Elsholtz H . Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J Biol Chem. 2002; 277(39):35819-25. DOI: 10.1074/jbc.M202920200. View

13.

Leverrier S, Vallentin A, Joubert D . Positive feedback of protein kinase C proteolytic activation during apoptosis. Biochem J. 2002; 368(Pt 3):905-13. PMC: 1223044. DOI: 10.1042/BJ20021253. View

14.

Banihashemi B, Albert P . Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements. Mol Endocrinol. 2002; 16(10):2393-404. DOI: 10.1210/me.2001-0220. View

15.

Iaccarino C, Samad T, Mathis C, Kercret H, Picetti R, Borrelli E . Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci U S A. 2002; 99(22):14530-5. PMC: 137917. DOI: 10.1073/pnas.222319599. View

16.

An J, Cho S, Jeong D, Park K, Ahn Y, Baik J . Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol. 2003; 206(1-2):49-62. DOI: 10.1016/s0303-7207(03)00236-3. View

17.

Bevan J, Webster J, BURKE C, Scanlon M . Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992; 13(2):220-40. DOI: 10.1210/edrv-13-2-220. View

18.

Wu G . The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther. 2004; 3(2):156-61. DOI: 10.4161/cbt.3.2.614. View

19.

Okada H, Mak T . Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004; 4(8):592-603. DOI: 10.1038/nrc1412. View

20.

Bursch W . Multiple cell death programs: Charon's lifts to Hades. FEMS Yeast Res. 2004; 5(2):101-10. DOI: 10.1016/j.femsyr.2004.07.006. View